UNSPSC 51172161: Ambucetamide hydrochloride

This classification denotes an antispasmotic agent with the molecular formula C17H28N2O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M010V3MAJ. European Medicines Agency schedules ambucetamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00428MIG. Most nations, for tariff and trade purposes, schedule ambucetamide hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, AMBUCETAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CCCCN(CCCC)C(C1CCC(CC1)OC)C(=O)N.CL.

UNSPSC 51172161 Ambucetamide hydrochloride is a Commodity code whose recent activity shows little alignment with the code's nominal pharmaceutical-ingredient scope. The three recent state and local opportunities associated with this code address offender drug testing services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution through cooperative purchasing — none of which involve ambucetamide hydrochloride as a procured product or active ingredient. The Collin County Community Supervision and Corrections Department RFP solicits specimen collection and drug testing services (immunoassay screening with LC/MS/MS or GC/MS confirmation, oral fluid, and hair testing) rather than the specific pharmaceutical compound the code names. The Texas Health and Human Services Commission RFI on Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions seeks vendor capacity for general prescription programs without naming specific drugs. The Minnesota Multistate Cooperative Purchasing Alliance RFP covers generic multi-source pharmaceuticals and OTC products across broad therapeutic categories, not ambucetamide hydrochloride in particular.

Activity under this code spans state health-and-human-services agencies, county corrections departments, and multi-state cooperative purchasing alliances, with the most recent opportunities originating in Texas (Collin County and HHS Commission) and Minnesota. The Collin County RFP for offender drug testing services carries a response deadline of July 23, 2026, an estimated contract value of $600,000 over a two-year initial term with three optional one-year renewals, and an anticipated award date of August 10, 2026. The Minnesota MMCAP RFP for generic pharmaceuticals closed with a March 26, 2026 deadline and covers products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) across multiple state and local government facilities with an effective date of July 1, 2026. The code shows minimal recent activity directly tied to ambucetamide hydrochloride procurement and warrants verification of coding accuracy against actual buying patterns before pursuing opportunities listed under it.